YBGJ (Yubo International Biotech) OCF Margin %: 0.00% (As of Mar. 2026)


What is Yubo International Biotech OCF Margin %?

Yubo International Biotech YBGJ -0.06% OCF Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Yubo International Biotech ranks worse than 98.16% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Yubo International Biotech's Cash Flow from Operations for the three months ended in Mar. 2026 was $-0.21 Mil. Yubo International Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Yubo International Biotech's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Yubo International Biotech's current OCF Yield % is -58.49%.

The historical rank and industry rank for Yubo International Biotech's OCF Margin % or its related term are showing as below:

YBGJ' s OCF Margin % Range Over the Past 10 Years
Min: -44600   Med: -350.02   Max: 7.46
Current: -5483.33

During the past 6 years, the highest OCF Margin % of Yubo International Biotech was 7.46%. The lowest was -44600.00%. And the median was -350.02%.

YBGJ's OCF Margin % is ranked worse than
98.16% of 816 companies
in the Medical Devices & Instruments industry
Industry Median: 5.785 vs YBGJ: -5483.33

Yubo International Biotech OCF Margin % Related Terms

Yubo International Biotech OCF Margin % Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech OCF Margin % Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -82.07 -577.88 -122.15 -44,600.00 -7,025.00

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1,075.00 0.00

YBGJ vs GCTK, ECIA, RSCF: OCF Margin % Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech OCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's OCF Margin % falls into.


Yubo International Biotech OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Yubo International Biotech's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.843/0.012
=-7,025.00 %

Yubo International Biotech's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.207/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Yubo International Biotech (YBGJ) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Yubo International Biotech and its competitors. According to the industry distribution chart, Yubo International Biotech ranks #801 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is Yubo International Biotech's OCF Margin % too high?
Yubo International Biotech's current OCF Margin % is 0.00%. Based on the distribution chart, Yubo International Biotech ranks #801 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Yubo International Biotech's OCF Margin % compare to GCTK and ECIA?
According to the Medical Devices & Instruments industry distribution chart, Yubo International Biotech ranks #801 out of 816 companies for OCF Margin %. This places Yubo International Biotech in the lower half of its industry. The industry median OCF Margin % is 5.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.79, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.